Analytical Data
-
基因名
CD19
- Application
-
别名
B-lymphocyte surface antigen B4 Differentiation antigen CD19 T-cell surface antigen Leu-12 CD_antigen: CD19
-
种属
Human
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P15391
-
表达区间
20-291aa
-
分子量
34.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD19 is a critical protein that serves as a pan-B cell marker and plays a pivotal role in B cell development, activation, and differentiation. Its significance in the context of immunotherapy, particularly in the treatment of B cell malignancies such as leukemia and lymphoma, has spurred extensive research into CD19-targeted therapies. The advent of chimeric antigen receptor (CAR) T-cell therapy has highlighted the therapeutic potential of engineering T cells to express receptors that specifically target CD19, leading to remarkable clinical outcomes. However, there are challenges, including antigen escape and the development of resistance, which necessitate the exploration of CD19 as a recombinant protein for understanding its structural and functional properties. Researchers are focusing on producing CD19 recombinant proteins to analyze their binding affinities, elucidating the mechanisms of immune evasion, and developing improved therapeutic strategies. Additionally, the study of CD19's signaling pathways and its interactions with other molecules in the immune system may provide insights into enhancing the efficacy and safety of CD19-targeted therapies. Through these investigations, the ultimate goal is to refine existing treatment modalities and contribute to the advancement of personalized medicine in oncology, offering new hope for patients with B cell-related disorders.
